Pipeline-In-A-Pill: Still A Winning Strategy?
Executive Summary
“Pipeline-in-a-pill” has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.
You may also be interested in...
Gilead Made Gains In Oncology, Though Virology Remains King
Pipeline-in-a-product approaches have become popular in biopharma, and Gilead has been making significant strides.
Pandemic Perspectives: The Lost Trials Of 2020
New development programs fell sharply in the early part of the year as COVID-19 spread around the world, but activity picked up in the second half. Oncology trials rebounded strongly and infectious disease trials ballooned, but autoimmune and CNS studies took a hit.
Pandemic Perspectives: Pharma Must Not Let Its COVID-19 Halo Slip
Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination. Consequently, industry perception scores have ticked upwards sharply, albeit from a low base.